FEATURED ARTICLES

• Expertise, Flexibility In Lipid Nanoparticle Clinical Manufacturing

  Explore the unique capabilities at a Vancouver, Canada site for clinical-scale manufacture of lipid nanoparticles (LNPs).

• Benefits Of Microparticle Technology For Oral Drug Solubility Enhancement

  Spray-dried dispersions, hot-melt extrusion, and solubilizing excipients are common solubility enhancement techniques, but new developments to maximize amorphous solid dispersion benefits are needed.

• An Insoluble Problem? Oral Drug Solubility With Functional Polymers

  Review the basics of solubility enhancement and the formulation and manufacture of products that enhance solubility and common questions on the topic.

• Biodegradable Polymers For Parenteral Drug Delivery

  Long-acting, complex drug delivery products, particularly those based on injectable microparticles, nanoparticles, and implants, are among the most attractive parenteral products.

• How Can Pharmaceutical Manufacturing Become Greener?

  Dr. Jochen Becker, Global Project Manager at Evonik, discusses overcoming the challenges for pharma to become greener and synergies between green chemistry and pharma manufacturing.

• Lipid Nanoparticle Development, Manufacturing Advance Novel Therapeutics

  An effective partner must possess the necessary unique analytical capabilities for LNP characterization and the ability to support clients from concept to commercialization.

• Cell Food: How Smart Media Formulations Drive Cell Culture Performance

  Efficient drug production through cell culture depends on the complex interplay between the drug molecule, the cell, and the process. How can you balance cell growth and productivity?

• Seizing Opportunity: Disruptive Forces In Advanced Cell Culture Tech

  The market for biological drugs continues to grow at an impressive pace over the past years. Explore three key trends that will underpin the sustainable growth of biopharma beyond COVID-19.

• Developing Life-Saving Medicines Through Cell Culture Technologies

  Evonik Health Care's Dr. Martin Schilling and Johns Hopkins University Professor Michael Betenbaugh discuss advances and trends in cell culture-based production of biological drugs.

• How mRNA Technology Is Shaping The Future Of Medicine

  Discover how mRNA technologies open the doors to a whole range of new gene therapies and the role of lipid nanoparticles (LNPs) in current and future developments.

• Exclusive Synthesis - API, HPAPI, And Intermediates

  Evonik is one of the world's top 3 CMOs for API and intermediates. The brochure offers insight into their capabilities and the technologies they use to address the specific needs of the largest and most complex synthesis problems life science companies face today. 

• Optimizing Gastric Resistance In Complex Oral Drug Products

  Functional capsules improve a targeted drug delivery strategy and allow the use of more sensitive active molecules. A newly launched platform of ready-to-fill capsules is free from animal-derived products.

• LNPs vs. Conventional Liposomes: Core Structural And Manufacturing Differences

  Key differences exist between liposomes and lipid nanoparticles (LNPs), not only in their target applications, but with their actual morphology, composition, and manufacturing process.

• Developing The Right Oral Dosage Form For Pediatric Medicines

  The selection of the right formulation is critical for the development of drug products for pediatric populations. The developmental status influences the dosage form and strength, taste or odor masking, and swallowability. Review some key factors to consider during initial formulation development.

• Post COVID-19: Pharma Supply Chain Shifts To A Regional Model

  The pandemic has highlighted vulnerabilities in the global supply chain. To reduce risk, initial steps are being taken to review how to increase local production capacities and tighten potential supply chain gaps.

• Why A Modular Continuous Pilot Plant Might Be Your Flow Chemistry Solution

  About the size of a shipping container, a Modular Continuous Pilot plant features a flexible, modular configuration that can enable a wide range of reactor types within a small and cost-effective footprint.

• Polymeric Implants, Formulations For Intravitreal Administration

  Polymeric formulations such as intra-ocular implants designed for the precise intravitreal delivery of drug products represent one of the most promising, yet challenging, areas of pharmaceutical focus.

• Why Aren't We Using Reformulation More For New Injectable Drug Products?

  With the significant financial costs and clinical risks involved in bringing a new injectable drug product to market, why isn’t reformulation or repurposing being used more often to meet these challenges? This interview with Dr. Tom Tice, one of the world’s leading experts on extended release injectables and implants, reviews current and emerging areas of reformulation focus and some best practices to get your strategy right.

• Cell Culture Media Dipeptides For Biopharma Process Improvement

  With the right selection of dipeptides, keto acids, special amino acids or other derivatives at hand, biopharma companies can realize substantial process improvements.

• Lipid Nanoparticle Delivery Tech: Beyond mRNA Vaccines

  What applications are being explored for lipid nanoparticle delivery technologies? Dr. Jay Natarajan, Director of R&D, competence center for LNP technology, answers questions here.

• Reviewing Formulation Technologies For Nanomedicines

  During a company's nanomedicine development program, selecting the right drug delivery technology is key. Deciding which is most suitable for an API must be determined by a complex array of factors.

• Ready-To-Use Excipients Can Now Solve Five Key Functional Challenges

  The market for oral drug products with an immediate release profile continues to move towards the development of more complex dosage forms designed to address specific functional or application requirements. While each formulation is different, customers most commonly want solutions to some combination of these five key challenges.

• Formulation, Manufacturing Capabilities For Cell & Gene Therapies

  The engagement of a CDMO partner with a broad portfolio of cell and gene therapy delivery technologies, a strong formulation track record and manufacturing flexibility is the preferred pathway for success.

• Outsourcing Microbial Fermentation To A CMO: Key Considerations

  Advances in synthetic biology and genetic engineering have fueled the potential of fermentation-based manufacturing. Here we examine key trends and  challenges to the approach.

• Developing The Highest Purity PEGs, mPEGs

  Few suppliers of standard or custom PEGs and mPEGs have the necessary competencies to address quality and purity requirements or to overcome technical manufacturing challenges.

• Advantages In The Continuous Manufacturing Of APIs And Intermediates Under cGMP Conditions

  Several drug products utilizing continuous manufacturing processes have been approved by the FDA, with many others in clinical development. Review the challenges and opportunities for the use of continuous manufacturing for APIs and intermediates.

• Boost Cys-Solubility, Performance In Cell Culture Media Apps

  While the solubility of free L-Cysteine is high at neutral pH, the applicable concentration in basal and feed media is limited. Read more about an available solution for solubility and performance challenges.

• Enhancing Stability, Survival & Performance Of Microbiome-Based Products

  For pharma and biotech companies focused on the development of microbiome products, it's important to develop oral dosage forms that can deliver specific formulation or application outcomes. 

• Enabling Enteric Protection And Rapid Release In The Upper Small Intestine

  For many complex drug products targeting the small intestine or ileocolonic region, enteric protection on its own is insufficient to maximize absorption and enhance bioavailability. 

• Highly Potent APIs Are Becoming More Potent And Complex

  Dr. Andreas Meudt, the global head of Exclusive Synthesis for Evonik, shares his thoughts on key growth trends for HPAPIs and why more pharma companies are outsourcing their production to contract specialists.

• Emerging Trends, CMO Solutions For Protein Fermentation

  To meet growing market demand for the use of protein-based products that have a sustainable ecological footprint, substantial efforts are now underway to utilize microbial fermentation-based processes.

• Cell Culture Media Ingredients: Optimized Stability And Solubility

  Cell culture media used in biopharma production have come a long way in recent decades. This interview discusses key solubility, stability and other challenges that many biopharma companies still face.

• Lipid Nanoparticles Are Having A Breakout Moment

  After more than 25 years of commercial use with almost 20 parenteral drug products, LNPs are having a breakout moment. Their potential has only become clear to many since COVID-19.

• A New Aseptic Solution For The Filling Of Complex Parenterals In Powder, Liquid Or Suspension Form

  Traditional filling lines lack the necessary versatility to address the growing number of complex and personalized parenteral drug products that are now being brought to market. Evonik has recently qualified a new modular aseptic filling platform that will efficiently fill drug products in powder, liquid, suspension or combination form.

• Five Key Tips To Enhance The Solubility Of Your Oral Drug Products

  Poor solubility used to be one of the main showstoppers during the development of oral drug products. How can pharma companies minimize project risk and development costs, select the right excipients, equipment and process technologies to complement their API and dosage form, and hopefully also enable higher drug loadings and improve stability? Following are five key factors that companies should keep in mind to help ensure their path to solubility enhancement is as seamless and as low risk as possible.

• Optimize Development And Upscale Of API/HPAPI And Fermentation Projects

  Discover some of the key expectations of customers who are reviewing CMOs to support the development and upscaling of their next major project.